RxDoctor Payments Data

Alberto Corica, MD

Urology · Tucson, AZNPI 1194927376

Payments from drug & device makers

$4,994in general payments, 2019–2025

Across 141 payments — averaging $35.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$1K
  • Procept Biorobotics Corporation$627
  • Astellas Pharma US Inc$489
  • Pfizer$459
  • Teleflex LLC$424
  • Johnson & Johnson$267
  • plus $2K from 18 others

What the payments were for

  • Travel & lodging$1,25225%
  • Food & beverage$3,38968%
  • Education$3537%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,994 in reported general payments places this provider in the 50th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$444,939
Medicare patients
315
Services billed
3,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide27$373,430
Lupron DepotLeuprolide Acetate17$152,532
GemtesaVibegron117$84,432
MyrbetriqMirabegron90$44,607
Testosterone22$4,161
Tamsulosin Hcl343$3,644
Ciprofloxacin Hcl227$1,119
Finasteride72$924
Oxybutynin Chloride ErOxybutynin Chloride40$596
Levofloxacin46$163
Cephalexin17$156
NitrofurantoinNitrofurantoin Macrocrystal16$145
Acetaminophen-CodeineAcetaminophen With Codeine36$124
Oxybutynin Chloride22$116
Testosterone Cypionate16$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$489$418,037117 claims
Sumitomo Pharma America, Inc.Gemtesa$98$84,432117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 269 urology providers in Arizona.

Other urology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →